Main Menu

NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Fresenius Kabi Oncology Limited (NSE: FKONCO)

 
FKONCO Technical Analysis
1
As on N/A FKONCO SHARE Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

FKONCOSHARE Price

Open N/A Change Price %
High N/A 1 Day N/A N/A
Low N/A 1 Week N/A N/A
Close N/A 1 Month N/A N/A
Volume N/A 1 Year N/A N/A
52 Week High N/A | 52 Week Low N/A
 
NSE INDIA Most Active Stocks
IDEA 7.37 1.94%
YESBANK 21.55 0.19%
EASEMYTRIP 11.92 0.00%
BHARTIARTL 1814.00 -2.85%
IRFC 138.61 6.43%
IFCI 51.77 15.69%
SUZLON 61.08 -0.23%
BEL 363.90 3.85%
RPOWER 45.07 1.74%
HCC 30.42 8.14%
 
NSE INDIA Top Gainers Stocks
NUCLEUS 1186.25 20.00%
PKTEA 785.60 19.99%
ZEELEARN 7.87 19.97%
PARAS 1799.50 18.82%
ONWARDTEC 313.00 17.76%
BPL 87.74 16.63%
BPL 87.74 16.63%
PEARLPOLY 33.75 16.34%
IFCI 51.77 15.69%
IFCI 51.77 15.69%
 
NSE INDIA Top Losers Stocks
KHAITANLTD 107.80 -8.14%
SOLARA 477.40 -7.94%
PARADEEP 144.93 -7.80%
BANSWRAS 143.53 -7.79%
NEULANDLAB 11056.00 -6.77%
DATAMATICS 616.75 -6.58%
NOCIL 184.18 -6.16%
EUROTEXIND 13.42 -6.09%
MANORAMA 1384.20 -5.68%
PRICOLLTD 438.50 -5.64%
 
 
FKONCO
Daily Charts		 FKONCO
Intraday Charts		 Whats New @
Bazaartrend		 FKONCO
Free Analysis
 
FKONCO Important Levels Intraday
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
 
FKONCO Target May 2025
Share
4th UP Target
3rd UP Target
2nd UP Target
1st UP Target
1st DOWN Target
2nd DOWN Target
3rd DOWN Target
4th DOWN Target
 
FKONCO Weekly Target
4th UP Target
3rd UP Target
2nd UP Target
1st UP Target
1st DOWN Target
2nd DOWN Target
3rd DOWN Target
4th DOWN Target
 
FKONCO Target2025
4th UP Target
3rd UP Target
2nd UP Target
1st UP Target
1st DOWN Target
2nd DOWN Target
3rd DOWN Target
4th DOWN Target
 
Fresenius Kabi Oncology Limited ( NSE INDIA Symbol : FKONCO )
Sector : Pharmaceuticals And Other Stocks in Same Sector
 
FKONCO Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
 Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 37.02 Sideways
MFI (14) MFI is 24.72 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Short Sell 1076.00
10 Day Avg Volume Traded -18.82 % Less then 10 Day Average Volume
 
FKONCO Other Details
Segment EQ
Market Capital 3824046080.00
Sector Pharmaceuticals
Industry
Offical website >
 
FKONCO Address
FKONCO
 N/A
 
FKONCO Latest News
 
Your Comments and Response on Fresenius Kabi Oncology Limited
 
FKONCO Business Profile
Dabur Pharma (DABURPH) is a specialty pharmaceuticals company with a focus on oncology. Earlier a part of Dabur Industries, the company completed the demerger process in December 2003. The non-executive chairman of the company is Mohit Burman and Dr. Anand C. Burman, the managing director. The fully integrated pharmaceutical business of Dabur Pharma covers the oral and injectable finished dosage forms and active pharmaceutical ingredients and intermediates. Products include anti-cancer drugs like Anastrozole, Oxaliplatin, Zoledronic Acid, etc; drug intermediates like Baccatin III, Epoxy Propoxy Carbazole, etc; calcium regulators like Alendronate Sodium BP. The company has its manufacturing units for finished dosage forms in Bordon (UK) and Baddi (India), while the active pharmaceutical ingredients (APIs) are manufactured in Kalyani (India) and some products come from Dabur India`s Sahibabad facilities. The company launched Paclitaxel Nanoparticles, an indigenously developed novel drug delivery system (NDDS) and received final approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Epirubicin injection 50mg and 200mg. The company acquired the entire oncology sales and distribution business from its partner Biosciences Co. in Thailand, while its subsidiary Dabrur Oncology Plc. set up Dabur Pharma US, Inc. to handle sales and marketing in US. The company has a 10-year exclusive agreement with Abbott Labs for generics in the US market. The company has overseas offices in UK, Malaysia, Russia, Thailand and Philippines. Products are available in more than 40 countries across the globe through a marketing network including Asia Pacific, Commonwealth of Independent States, India, Latin America, North America and the European Union. It recently forayed into Pakistan and Turkmenistan. The current market capitalization stands at Rs 2,068.04 crore. The company has reported a standalone sales of Rs 96.15 crore and a Net Loss of Rs 44.79 crore for the quarter ended September 2013. The company management includes Rakesh Bhargava - Non Executive Chairman, Peter F Nilsson - Managing Director & CEO, Dilip G Shah - Ind. Non-Executive Director, Michael Schonhofen - Non Executive Director, Gerrit Steen - Non Executive Director, Naresh Trehan - Ind. Non-Executive Director, Patricia Grigoleit - Non Executive Director, Rajiv Lochan Jain - Independent Director. The Registered office is at B - 310, Som Datt Chambers - I,,Bhikaji Cama Place New Delhi,Delhi - 110066 and corporate office is at Plot No.11, Echelon Institutional Area,Sector -32,Gurgaon, Haryana - 122001.
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service